Christopher Yea is CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 85,676 shares of KALV, which is worth approximately $1.06 Million. The most recent transaction as insider was on Feb 23, 2021, when has been sold 15,000 shares (Common Stock) at a price of $33.49 per share, resulting in proceeds of $502,350. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 85.7K
7.0% 3M change
105.65% 12M change
Total Value Held $1.06 Million

Christopher Yea Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 23 2021
SELL
Open market or private sale
$502,350 $33.49 p/Share
15,000 Reduced 23.82%
47,969 Common Stock
Oct 29 2020
SELL
Open market or private sale
$87,400 $17.48 p/Share
5,000 Reduced 7.36%
62,969 Common Stock
Oct 21 2020
SELL
Open market or private sale
$110,907 $18.35 p/Share
6,044 Reduced 8.17%
67,969 Common Stock
Oct 20 2020
SELL
Open market or private sale
$140,097 $17.64 p/Share
7,942 Reduced 9.69%
74,013 Common Stock
Oct 16 2020
SELL
Open market or private sale
$15,538 $17.0 p/Share
914 Reduced 1.1%
81,955 Common Stock
CY

Christopher Yea

CHIEF DEVELOPMENT OFFICER
Cambridge, MA

Track Institutional and Insider Activities on KALV

Follow KalVista Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

News

Receive news related to KalVista Pharmaceuticals, Inc.

Track Activities on KALV